Conditions: Vitreomacular Traction Vitreomacular Adhesion
Keywords: Vitreomacular traction Symptomatic vitreomacular adhesion Ocriplasmin JETREA
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 628
Healthy volunteers: no

Brief summary:
The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA®) over a 6-month follow-up period.

Detailed description:
After receiving a single intravitreal injection as per country's product label (Day 0), subjects were followed for a 6-month period (Day 180).

Arms:
arm 1: Ocriplasmin 0.125 mg in a 0.1 mL volume administered as a single dose by intravitreal injection

Interventions: intervention 1: Ocriplasmin
Intervention descriptions: intervention 1: 0.5 mg/0.2 mL solution for injection

Protocol document: